Dual-Targeted Drug Design of HER2 and HSP90 by CoMFA Model and Pharmacophore Analysis

2009 2nd International Conference on Biomedical Engineering and Informatics ◽

10.1109/bmei.2009.5305352 ◽

2009 ◽

Author(s):

Hung-Jin Huang ◽

Da-Tian Bau ◽

Ming-Hsui Tsai ◽

Yuan-Man Hsu ◽

Tin-Yun Ho ◽

...

Keyword(s):

Drug Design ◽

Comfa Model ◽

Targeted Drug

Download Full-text

The Development of Epigenetics and Related Inhibitors for Targeted Drug Design in Cancer Therapy

Current Topics in Medicinal Chemistry ◽

10.2174/1568026618666181115092623 ◽

2019 ◽

Vol 18 (28) ◽

pp. 2380-2394 ◽

Cited By ~ 4

Author(s):

Na Liu ◽

Rongtong Zhao ◽

Yue Ma ◽

Dongyuan Wang ◽

Chen Yan ◽

...

Keyword(s):

Drug Design ◽

Rapid Development ◽

Epigenetic Changes ◽

Disease Treatment ◽

Nucleosome Remodeling ◽

Epigenetic Modifiers ◽

The Us ◽

Targeted Drug ◽

Heritable Change ◽

Lymphoma Therapy

Epigenetics process is the heritable change in gene function that does not involve changes in the DNA sequence. Until now, several types of epigenetic mechanisms have been characterized, including DNA methylation, histone modification (acetylation, methylation, etc.), nucleosome remodeling, and noncoding RNAs. With the biological investigations of these modifiers, some of them are identified as promoters in the process of various diseases, such as cancer, cardiovascular disease and virus infection. Epigenetic changes may serve as potential “first hits” for tumorigenesis. Hence, targeting epigenetic modifiers is being considered as a promising way for disease treatment. To date, six agents in two epigenetic target classes (DNMT and HDAC) have been approved by the US Food and Drug Administration (FDA). Most of these drugs are applied in leukemia, lymphoma therapy, or are combined with other drugs for the treatment of solid tumor. Due to the rapid development of epigenetics and epigenetics targeted drugs, it is becoming an emerging area in targeted drug design.

Download Full-text